Open an account

Redhill Biopharma

RDHL · NASDAQ

$0.5073−$0.0023 (−0.45%)TodayMarket closed ·
Prev close $0.5096

About RDHL

RedHill Biopharma Ltd. engages in the development and commercialization of drugs for gastrointestinal (GI), infectious diseases, and oncology. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.

Employees
35
Headquarters
TEL AVIV-YAFO
Listed
Feb 1, 2011
Sector
Health Care
Industry
Pharmaceuticals
Website
redhillbio.com

RDHL key statistics

Market cap
4.45M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
929.31K
Volume
2
Open price
$0.4828
High today
$0.5199
Low today
$0.46
52 Week high
$2.14
52 Week low
$0.4351

Redhill Biopharma (RDHL) at a glance

As of Oct 21, 2026, Redhill Biopharma (RDHL) shares are priced at $0.5073, giving the company a market cap of 4.45M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.46 and $0.5199. The current price is 10.3% above the day's low and 2.4% below its high.

Volume so far is 2 shares, below the average of 929.31K shares a day.

Over the past year Redhill Biopharma has ranged from $0.4351 to $2.14, and now sits 4% of the way up that range.

Redhill Biopharma met or beat analyst EPS estimates in 0 of the last 8 quarters. In Q2 FY22 it reported -$200.00 per share against an estimate of -$30.60.

RDHL earnings

Earnings per share, reported against the analyst estimate

Didn’t beat the estimate in any of the last 8 quarters.

  1. Q3 FY20: reported -$500.00 per share against an estimate of -$161.16
  2. Q4 FY20: reported -$700.00 per share against an estimate of -$247.35
  3. Q1 FY21: reported -$500.00 per share against an estimate of -$346.80
  4. Q2 FY21: reported -$600.00 per share against an estimate of -$120.36
  5. Q3 FY21: reported -$500.00 per share against an estimate of -$210.80
  6. Q4 FY21: reported -$500.00 per share against an estimate of -$336.60
  7. Q1 FY22: reported -$300.00 per share against an estimate of -$234.60
  8. Q2 FY22: reported -$200.00 per share against an estimate of -$30.60

RDHL news

  • Press releasePRNewswire

    $2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma

  • Press releaseGlobe Newswire

    Small Caps Test Their 200-Day Line as Yields Grind Higher and Earnings Season Stirs

  • Press releasePRNewswire

    Weekly Losses Deepen As Small Caps Lag And Yields Edge Higher Into Earnings Gauntlet

  • Press releasePRNewswire

    RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results

  • Press releasePRNewswire

    RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®

  • Vandana Singh

    Redhill Biopharma Stock Doubles In One Session — Here's Why

  • Market-Moving News for August 31st

  • Press releasePRNewswire

    RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities

Similar companies

Companies in the same industry as Redhill Biopharma

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.